Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

61. [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]

[Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public (...) d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] L'Institut national d'excellence en sante et en services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Institut national d'excellence en sante et en services sociaux (INESSS

2012 Health Technology Assessment (HTA) Database.

62. Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. (Abstract)

Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. 22910967 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. JC2-13 10.7326/0003-4819-157-4-201208210-02013 Koretz Ronald L RL Olive View-UCLA Medical Center Sylmar, California, USA. eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

63. Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial Full Text available with Trip Pro

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear.We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor (...) in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial. The primary end point rates were higher for individuals on a PPI (n=6539) compared with those not on a PPI (n=12 060) at randomization in both the clopidogrel (13.0% versus 10.9%; adjusted hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.04-1.38) and ticagrelor (11.0% versus 9.2%; HR, 1.24; 95% CI, 1.07-1.45) groups. Patients on non-PPI gastrointestinal drugs had similar primary end point

2012 EvidenceUpdates Controlled trial quality: predicted high

64. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

65. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Full Text available with Trip Pro

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. To examine the association between chronic use of proton pump inhibitors (PPIs) and risk of hip fracture.Prospective cohort study.Nurses' Health Study, which originally recruited from the 11 most populous states in the US.79,899 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of PPIs and other risk factors biennially since 2000

2012 BMJ

66. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis

Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

67. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

68. Proton pump inhibitors in long-term use: reports of hypomagnesaemia

Proton pump inhibitors in long-term use: reports of hypomagnesaemia Proton pump inhibitors in long-term use: reports of hypomagnesaemia - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors in long-term use: reports of hypomagnesaemia Healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment. Published 11 December 2014 From: Therapeutic area: Contents Article (...) date: April 2012 Proton pump inhibitors (PPIs) are a class of drugs for the treatment of duodenal and gastric ulcers, and are used in combination with antibacterials for the eradication of Helicobacter pylori. They are also used to treat gastroesophageal reflux disease, dyspepsia, and Zolligner-Ellison syndrome and for prevention and treatment of ulcers associated with the use of non-steroidal anti-inflammatory drugs. The class of PPIs includes esomeprazole (Nexium), lansoprazole (Zoton

2012 MHRA Drug Safety Update

69. Proton pump inhibitors in long-term use: increased risk of fracture

Proton pump inhibitors in long-term use: increased risk of fracture Proton pump inhibitors in long-term use: increased risk of fracture - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors in long-term use: increased risk of fracture Recent epidemiological evidence of an increased risk of fracture with long-term use of proton pump inhibitors (PPIs). Published 11 December 2014 From: Therapeutic area: Contents Article date: April 2012 Observational studies

2012 MHRA Drug Safety Update

70. Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Article Text Prognosis Cohort study Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events David N Juurlink Statistics from Altmetric.com Commentary on: Charlot M , Grove EL , Hansen PR , et al . Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time

2012 Evidence-Based Medicine

71. Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Full Text available with Trip Pro

Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Article Text Therapeutics Randomised controlled trial Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors George Triadafilopoulos Statistics from Altmetric.com Commentary on: Galmiche JP , Hatlebakk J , Attwood

2012 Evidence-Based Medicine

72. Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness

Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence (...) be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Celecoxib versus Non-selective Non-steroidal Anti-Inflammatory Drugs and Proton Pump Inhibitors: Clinical Effectiveness, Safety, and Cost-Effectiveness

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

73. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Full Text available with Trip Pro

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Saini SD, Fendrick AM, Scheiman JM Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of proton-pump inhibitor (PPI) co-therapy to reduce dyspepsia in patients aged 50 years or older, receiving long-term, low-dose aspirin, for the secondary prevention of cardiovascular disease

2011 NHS Economic Evaluation Database.

74. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis

Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

75. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial Full Text available with Trip Pro

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy.double-blind, placebo-controlled, randomised, parallel-group

2011 EvidenceUpdates Controlled trial quality: predicted high

76. Proton pump inhibitor use and the antifracture efficacy of alendronate Full Text available with Trip Pro

Proton pump inhibitor use and the antifracture efficacy of alendronate Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures.Population-based, national

2011 EvidenceUpdates

77. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis

The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

78. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention (Abstract)

Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention The aim of the present study was to analyze the effect of drug exposure patterns of clopidogrel and proton pump inhibitors (PPIs) on the clinical outcomes after percutaneous coronary intervention (PCI). Previous analyses predominantly included discharge medications and did not explore the effect of the drug exposure patterns. We analyzed all-cause death, nonfatal myocardial infarction

2011 EvidenceUpdates

79. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention Full Text available with Trip Pro

Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding. Proton pump inhibitors (PPIs) may reduce upper GI bleeding. We estimate the cost-utility of aspirin treatment with or without a PPI for coronary heart disease (CHD) prevention among men at different risks for CHD and GI bleeding.We updated a Markov model to compare costs and outcomes of low-dose aspirin plus PPI (omeprazole, 20 mg/d

2011 EvidenceUpdates

80. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.